Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.

McSweeney MD, Price LSL, Wessler T, Ciociola EC, Herity LB, Piscitelli JA, DeWalle AC, Harris TN, Chan AKP, Saw RS, Hu P, Jennette JC, Forest MG, Cao Y, Montgomery SA, Zamboni WC, Lai SK.

J Control Release. 2019 Aug 24;311-312:138-146. doi: 10.1016/j.jconrel.2019.08.017. [Epub ahead of print]

PMID:
31454530
2.

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA.

Nat Commun. 2019 Jul 18;10(1):3163. doi: 10.1038/s41467-019-11107-x.

3.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
4.

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM.

Lancet Oncol. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. Epub 2019 Jun 3.

PMID:
31171444
5.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.

Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.

PMID:
31160251
6.

False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.

Nijhuis AAG, Dieng M, Khanna N, Lord SJ, Dalton J, Menzies AM, Turner RM, Allen J, Saw RPM, Nieweg OE, Thompson JF, Morton RL.

Ann Surg Oncol. 2019 Jun;26(6):1860-1868. doi: 10.1245/s10434-019-07311-0. Epub 2019 Mar 25.

PMID:
30911946
7.

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H.

Ann Oncol. 2019 May 1;30(5):815-822. doi: 10.1093/annonc/mdz075.

8.

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.

Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Oncotarget. 2019 Jan 29;10(9):930-941. doi: 10.18632/oncotarget.26584. eCollection 2019 Jan 29.

9.

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.

Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A, Allen R, Allanson B, Saw RPM, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, Scolyer RA.

Clin Cancer Res. 2019 Jun 1;25(11):3247-3258. doi: 10.1158/1078-0432.CCR-18-4011. Epub 2019 Feb 18.

PMID:
30777877
10.

Molecular Genomic Profiling of Melanocytic Nevi.

Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RPM, Stretch JR, McArthur GA, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS.

J Invest Dermatol. 2019 Aug;139(8):1762-1768. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14.

PMID:
30772300
11.

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS.

Cancer Cell. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003.

PMID:
30753825
12.

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.

Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, Menzies AM, Long GV, Scolyer RA, Wilmott JS.

Oncoimmunology. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. eCollection 2019.

PMID:
30713793
13.

Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.

Gide TN, Allanson BM, Menzies AM, Ferguson PM, Madore J, Saw RPM, Thompson JF, Long GV, Wilmott JS, Scolyer RA.

Histopathology. 2019 May;74(6):817-828. doi: 10.1111/his.13814.

PMID:
30589949
14.

Subungual Melanoma of the Hand.

Chakera AH, Quinn MJ, Lo S, Drummond M, Haydu LE, Bond JS, Stretch JR, Saw RPM, Lee KJ, McCarthy WH, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2019 Apr;26(4):1035-1043. doi: 10.1245/s10434-018-07094-w. Epub 2018 Dec 18.

PMID:
30565042
15.

Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens.

Friedman EB, Dodds TJ, Lo S, Ferguson PM, Beck M, Saw RPM, Stretch JR, Lee KK, Nieweg OE, Spillane AJ, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2019 Jan;26(1):25-32. doi: 10.1245/s10434-018-6858-y. Epub 2018 Oct 16.

PMID:
30327975
16.

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.

Wilmott JS, Johansson PA, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard AL, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RPM, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA.

Int J Cancer. 2019 Mar 1;144(5):1049-1060. doi: 10.1002/ijc.31791. Epub 2018 Nov 21.

PMID:
30178487
17.

Discrimination, Bullying and Harassment in Surgery: A Systematic Review and Meta-analysis.

Huang Y, Chua TC, Saw RPM, Young CJ.

World J Surg. 2018 Dec;42(12):3867-3873. doi: 10.1007/s00268-018-4716-5.

PMID:
29971462
18.

Correction to: 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study.

Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Thompson JF, Peach H, Oudit D, Geh J, Dziewulsk P, Wilson E, Matteucci P, Pritchard-Jones R, Olofsson Bagge R, Wright FC, Crampton N, Cassell O, Jallali N, Berger A, Kelly J, Hamilton S, Durrani A, Lo S, Paton E, Henderson MA.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):991. doi: 10.1245/s10434-018-6612-5.

PMID:
29947003
19.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

20.

Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma.

Lim WY, Turner RM, Morton RL, Jenkins MC, Irwig L, Webster AC, Dieng M, Saw RPM, Guitera P, Low D, Low C, Bell KJL.

BMC Health Serv Res. 2018 Jun 20;18(1):477. doi: 10.1186/s12913-018-3291-7.

21.

1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study.

Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Thompson JF, Peach H, Oudit D, Geh J, Dziewulski P, Wilson E, Matteucci P, Pritchard-Jones R, Olofsson Bagge R, Wright FC, Crampton N, Cassell O, Jallali N, Berger A, Kelly J, Hamilton S, Durrani A, Lo S, Paton E, Henderson MA.

Ann Surg Oncol. 2018 Sep;25(9):2541-2549. doi: 10.1245/s10434-018-6470-1. Epub 2018 May 30. Erratum in: Ann Surg Oncol. 2018 Jun 26;:. Thompson JF [added].

22.

Metastatic Melanoma to the Colon, Rectum, and Anus: A 50-Year Experience.

Park JS, Ng KS, Saw RPM, Thompson JF, Young CJ.

Ann Surg Oncol. 2018 Aug;25(8):2178-2183. doi: 10.1245/s10434-018-6451-4. Epub 2018 Apr 24.

PMID:
29691736
23.

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.

Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton WJ, Saw RPM, Thompson JF, Menzies AM, Long GV, Scolyer RA, Palendira U.

Clin Cancer Res. 2018 Jul 1;24(13):3036-3045. doi: 10.1158/1078-0432.CCR-17-2257. Epub 2018 Mar 29.

24.

Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma.

Lim WY, Morton RL, Turner RM, Jenkins MC, Guitera P, Irwig L, Webster AC, Dieng M, Saw RPM, Low D, Low C, Bell KJL.

JAMA Dermatol. 2018 Apr 1;154(4):420-427. doi: 10.1001/jamadermatol.2018.0021.

25.

Incidental detection of colorectal lesions by FDG PET/CT scans in melanoma patients.

Young CJ, Zahid A, Choy I, Thompson JF, Saw RPM.

Eur J Surg Oncol. 2017 Nov;43(11):2163-2169. doi: 10.1016/j.ejso.2017.09.012. Epub 2017 Sep 19.

PMID:
28964611
26.

Injuries in Australian Rules Football: An Overview of Injury Rates, Patterns, and Mechanisms Across All Levels of Play.

Saw R, Finch CF, Samra D, Baquie P, Cardoso T, Hope D, Orchard JW.

Sports Health. 2018 May/Jun;10(3):208-216. doi: 10.1177/1941738117726070. Epub 2017 Aug 21. Review.

27.

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Mod Pathol. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4.

28.

Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy 
and Targeted Therapy
.

Lomax AJ, Nielsen T, Visintin L, O'Carrigan B, Honeyball F, Shum B, Saw RPM, McNeil C.

Clin J Oncol Nurs. 2017 Aug 1;21(4):E93-E98. doi: 10.1188/17.CJON.E93-E98. Review.

PMID:
28738040
29.

Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.

Varey AHR, Goumas C, Hong AM, Mann GJ, Fogarty GB, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Lee KJ, Quinn MJ, Thompson JF, Scolyer RA.

Mod Pathol. 2017 Nov;30(11):1538-1550. doi: 10.1038/modpathol.2017.76. Epub 2017 Jul 21.

30.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

31.

Melanoma patient imaging in the era of effective systemic therapies.

Stodell M, Thompson JF, Emmett L, Uren RF, Kapoor R, Saw RPM.

Eur J Surg Oncol. 2017 Aug;43(8):1517-1527. doi: 10.1016/j.ejso.2017.05.014. Epub 2017 May 25. Review.

PMID:
28625798
32.

Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy.

Mattavelli I, Patuzzo R, Torri V, Gallino G, Maurichi A, Lamera M, Valeri B, Bolzonaro E, Barbieri C, Tolomio E, Moglia D, Nespoli AM, Galeone C, Saw R, Santinami M.

Eur J Surg Oncol. 2017 Aug;43(8):1536-1541. doi: 10.1016/j.ejso.2017.05.013. Epub 2017 May 25.

PMID:
28583789
33.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.

34.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
35.

Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.

Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, Stretch JR, McCarthy WH, Thompson JF.

J Clin Oncol. 2017 May 20;35(15):1721-1729. doi: 10.1200/JCO.2016.71.9393. Epub 2017 Apr 4.

PMID:
28375785
36.

Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications.

Morton RL, Tran A, Vessey JY, Rowbotham N, Winstanley J, Shannon K, Spillane AJ, Stretch J, Thompson JF, Saw RP.

Ann Surg Oncol. 2017 Aug;24(8):2071-2079. doi: 10.1245/s10434-017-5842-2. Epub 2017 Mar 20.

PMID:
28321690
37.

Fear of new or recurrent melanoma after treatment for localised melanoma.

Bell KJL, Mehta Y, Turner RM, Morton RL, Dieng M, Saw R, Guitera P, McCaffery K, Low D, Low C, Jenkins M, Irwig L, Webster AC.

Psychooncology. 2017 Nov;26(11):1784-1791. doi: 10.1002/pon.4366. Epub 2017 Feb 2.

PMID:
28052599
38.

5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.

Lee JJ, Vilain RE, Granter SR, Hu NR, Bresler SC, Xu S, Frank AH, Mihm MC Jr, Saw RP, Fletcher CD, Scolyer RA, Murphy GF, Lian CG.

J Cutan Pathol. 2017 Mar;44(3):249-255. doi: 10.1111/cup.12880. Epub 2017 Feb 6.

PMID:
28032662
39.

Pigmented lesions of the nail bed - Clinical assessment and biopsy.

Rtshiladze MA, Stretch JR, Stewart DA, Saw RP.

Aust Fam Physician. 2016 Nov;45(11):810-813.

40.

Workplace Bullying in Surgery.

Ling M, Young CJ, Shepherd HL, Mak C, Saw RP.

World J Surg. 2016 Nov;40(11):2560-2566.

PMID:
27624759
41.

Sentinel node biopsy in patients with intermediate and thick melanomas – A balanced view.

Saw R, Allan C, Barbour A, Ch'ng S, Coventry BJ, Gyorki D, Henderson M, Howle J, Hughes TM, Lee K, Neuhaus S, Saunders C, Shannon K, Smithers M, Speakman D, Spillane J, Stretch J.

Aust Fam Physician. 2015 Dec;44(12):876. No abstract available.

PMID:
27505913
42.

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.

Histopathology. 2016 Oct;69(4):680-6. doi: 10.1111/his.12992. Epub 2016 Jun 15.

PMID:
27151331
43.

The molecular profile of metastatic melanoma in Australia.

Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV.

Pathology. 2016 Feb;48(2):188-93. doi: 10.1016/j.pathol.2015.12.008. Epub 2016 Jan 18.

PMID:
27020391
44.

Attitudes and risk of withdrawal in general surgical registrars.

Keegan RJ, Saw R, De Loyde KJ, Young CJ.

N Z Med J. 2015 Nov 20;128(1425):61-8.

PMID:
26905988
45.

Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.

Busam KJ, Vilain RE, Lum T, Busam JA, Hollmann TJ, Saw RP, Coit DC, Scolyer RA, Wiesner T.

Am J Surg Pathol. 2016 Jun;40(6):786-95. doi: 10.1097/PAS.0000000000000611.

46.

The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study.

MacKenzie Ross AD, Haydu LE, Quinn MJ, Saw RP, Shannon KF, Spillane AJ, Stretch JR, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2016 Apr;23(4):1082-9. doi: 10.1245/s10434-015-4942-0. Epub 2015 Nov 11.

PMID:
26561405
47.

Laminated saccules: a residuum of an ovarian mature cystic teratoma.

Rahim A, Saw RM, Bailey J, Scurry J.

Pathology. 2015 Dec;47(7):710-1. doi: 10.1097/PAT.0000000000000338. No abstract available.

PMID:
26517630
48.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

49.

Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center.

Haydu LE, Stollman JT, Scolyer RA, Spillane AJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Bonenkamp JJ, Thompson JF.

Ann Surg Oncol. 2016 Apr;23(4):1071-81. doi: 10.1245/s10434-015-4575-3. Epub 2015 May 9.

PMID:
25956574
50.

Diverse presentations of acral melanoma.

Saw RP, Chakera AH, Stretch JR, Read RL.

Aust Fam Physician. 2015 Jan-Feb;44(1-2):43-5.

Supplemental Content

Support Center